Catalyst Pharmaceuticals, Inc.
US ˙ NasdaqCM ˙ US14888U1016

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionSei Investments Co
Latest Disclosed Ownership77,072 shares
Latest Disclosed Value $ 1,798,855
Sei Investments Co reports 0.56% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On February 13, 2026 - Sei Investments Co filed a 13F-HR form disclosing ownership of 77,072 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $1,798,860 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 76,642 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 0.56% during the quarter. The current value of the position is $2,410,812 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 77,072 430 0.56 1,799 19.15 0.0018
2025-11-13 2025-09-30 13F CATALYST PHARMACEUTICALS COM 14888U101 76,642 9,344 13.88 1,510 3.36 0.0016
2025-08-14 2025-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 67,298 -34,975 -34.20 1,460 -41.13 0.0017
2025-05-14 2025-03-31 13F/A-1 CATALYST PHARMACEUTICALS COM 14888U101 102,273 -14,045 -12.07 2,480 2.18 0.0032
2025-05-13 2025-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 116,433 115 2,494 0.0027
2025-02-11 2024-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 116,318 14,849 14.63 2,428 20.33 0.0031
2024-11-12 2024-09-30 13F CATALYST PHARMACEUTICALS COM 14888U101 101,469 17,011 20.14 2,018 54.20 0.0026
2024-08-13 2024-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 84,458 1,098 1.32 1,308 -1.51 0.0019
2024-05-07 2024-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 83,360 32,621 64.29 1,329 55.87 0.0019
2024-02-14 2023-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 50,739 8,483 20.08 853 72.82 0.0014
2023-11-14 2023-09-30 13F CATALYST PHARMACEUTICALS COM 14888U101 42,256 -3,241 -7.12 494 -19.31 0.0009
2023-08-11 2023-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 45,497 -29,640 -39.45 611 -50.92 0.0011
2023-05-12 2023-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 75,137 29,150 63.39 1,246 45.61 0.0023
2023-02-10 2022-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 45,987 -173,465 -79.04 855 -69.64 0.0019
2022-11-14 2022-09-30 13F CATALYST PHARMACEUTICALS COM 14888U101 219,452 -129,714 -37.15 2,816 15.65 0.0063
2022-08-15 2022-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 349,166 53,452 18.08 2,435 -0.41 0.0053
2022-05-13 2022-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 295,714 121,870 70.10 2,445 107.73 0.0049
2022-02-14 2021-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 173,844 0 0.00 1,177 27.80 0.0022
2021-11-12 2021-09-30 13F CATALYST PHARMACEUTICALS COM 14888U101 173,844 173,844 921 0.0019
2021-08-06 2021-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 0 -18,905 -100.00 0 -100.00
2021-05-12 2021-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 18,905 0 0.00 63 0.00 0.0002
2021-02-08 2020-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 18,905 0 0.00 63 12.50 0.0002
2020-12-04 2020-09-30 13F/A-1 CATALYST PHARMACEUTICALS COM 14888U101 18,905 -58,179 -75.47 56 -84.27 0.0002
2020-11-06 2020-09-30 13F CATALYST PHARMACEUTICALS COM 14888U101 18,905 -58,179 56 134.8355
2020-08-17 2020-06-30 13F/A-1 CATALYST PHARMACEUTICALS COM 14888U101 77,084 0 0.00 356 19.87 0.0011
2020-08-11 2020-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 12,768 -64,316 48 130.2026
2020-05-14 2020-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 77,084 64,316 503.73 297 518.75 0.0011
2020-02-06 2019-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 12,768 12,768 48 0.0001
2019-08-14 2019-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 0 -112,169 -100.00 0 -100.00
2019-05-15 2019-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 112,169 112,169 572 0.0019
2018-08-03 2018-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 0 -1,250 -100.00 0 -100.00
2018-05-11 2018-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 1,250 0 0.00 3 -40.00 0.0000
2018-02-08 2017-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 1,250 1,250 5 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.